Dermira Inc.

Empress Therapeutics CEO Jason Park explains his company’s approach to drug discovery and development as “bringing a genetic basis to small molecule drugs.” When the Cambridge, MA-based firm emerged

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Maruho Obtains Rights To GI-301 No

The most unusual aspect of the dozen applications with September 2023 goal dates at the US FDA is how unusual they aren’t. Standard reviews are the rule, even for the lone breakthrough therapy-designa

Evommune, Inc. recently closed a $57.5m series B financing that it believes will position the company to advance multiple novel drugs for a variety of autoimmune diseases toward value-creating cataly